511 related articles for article (PubMed ID: 21896288)
1. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
3. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
4. Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.
Betancor G; Álvarez M; Marcelli B; Andrés C; Martínez MA; Menéndez-Arias L
Nucleic Acids Res; 2015 Feb; 43(4):2259-70. PubMed ID: 25662223
[TBL] [Abstract][Full Text] [Related]
5. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
7. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
8. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
9. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
10. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
11. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
Ghosn J; Chaix ML; Delaugerre C
AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
15. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J; Stammers DK
Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
[TBL] [Abstract][Full Text] [Related]
17. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
18. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Stammers DK
J Mol Biol; 2004 Feb; 336(3):569-78. PubMed ID: 15095972
[TBL] [Abstract][Full Text] [Related]
20. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]